Publicaciones - IR Sant Pau

Buscar

08/07/2025 Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study

Bento, L, Gutiérrez, A, Martinez, C, Verdet, MCO, Sorribes, M, Caballero, AC, Peña, M, Pérez, A, Jiménez-Ubieto, A, Medina, L, Bastos-Oreiro, M, Caldas-González, PF, Navarro, B, Salcedo, I, Abrisqueta, P, Español, I, Cornago, J, Martín-Moro, F, García, L, Gómez, P, Varela, MR, Puente, M, Zanabili, J, Zudaire, T, Zeberio, I, del Campo, R, González, L, González, P, Blázquez, C, Rovira, J, Sitges, M, Franch-Sarto, M, Cabero, A, Mussetti, A, Montoro, J, Sampol, A, Sureda, A, Caballero, D, García-Sancho, AM. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study. Blood Advances. 2025; 9(13)DOI:10.1182/bloodadvances.2024015415. PMID:40163764. IF:7.100(Q1/2D).

01/07/2025 SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions

Rubio, MA, Cisa-Wieczorek, S, Mozos, A, Castellet, H, Bussaglia, E, Carricondo, M, Hernández-Alvarez, MI, Sierra, J, Nomdedéu, JF. SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions. ANNALS OF HEMATOLOGY. 2025; 104(7)DOI:10.1007/s00277-025-06458-z. PMID:40613901. IF:2.400(Q2/5D).

01/07/2025 Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials

Moreno, DF, Oriol, A, de la Rubia, J, Hernández, MT, Iñigo, MB, Palomera, L, de Arriba, F, González, Y, Teruel, AI, Pardo, JL, de la Guía, AL, Sampol, A, Ríos-Tamayo, R, Sureda, A, Gutiérrez, NC, Calasanz, MJ, Ramos, MLM, Mateos, MV, San Miguel, J, Lahuerta, JJ, Bladé, J, Rosiñol, L. Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials. Clinical Lymphoma Myeloma & Leukemia. 2025; 25(7)DOI:10.1016/j.clml.2025.01.014. PMID:39955256. IF:2.700(Q2/4D).

04/06/2025 Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

Gagelmann, N, de Witte, M, Peczynski, C, Boreland, W, Broers, AEC, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Errico, G, Bethge, W, Maertens, J, Stölzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kröger, N, Di Chio, MC, Finazzi, MC, Corral, LL, Rifón, J, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01315-8. PMID:40467580. IF:11.600(Q1/1D).

01/06/2025 Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia

Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

14/05/2025 Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations

Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).

01/05/2025 Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

Sobas, MA, Turki, AT, Ramiro, AV, Hernández-Sánchez, A, Elicegui, JM, González, T, Melchor, RA, Abáigar, M, Tur, L, Dall'Olio, D, Sträng, E, Tettero, JM, Castellani, G, Benner, A, Doehner, K, Thiede, C, Metzeler, KH, Haferlach, T, Damm, F, Ayala, R, Martínez-López, J, Mills, KI, Sierra, J, Lehmann, S, Della Porta, MG, Mayer, J, Reinhardt, D, Medina, RV, Schulze-Rath, R, Barbus, M, Hernández-Rivas, JM, Huntly, BJP, Ossenkoppele, G, Döhner, H, Bullinger, L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. HAEMATOLOGICA. 2025; 110(5)DOI:10.3324/haematol.2024.285805. PMID:39506894. IF:10.100(Q1/2D).

01/04/2025 CNS manifestations in acute and chronic graft-versus-host disease

Lambert, N, Forte, F, El Moussaoui, M, Monseur, J, Raus, N, Polushin, A, Michonneau, D, Shultz, C, Hogan, WJ, Balaguer-Roselló, A, Gil-Perotín, S, Brijs, J, Chauvet, P, Gavriilaki, M, Carre, M, Dulamea, AO, Chalandon, Y, Salmenniemi, U, Duminuco, A, Ram, R, García-Cadenas, I, Porto, G, Nguyen, S, Smallbone, P, González-Vicent, M, Santoro, JD, Willems, E, Baron, F, Servais, S, Beguin, Y, Maquet, P, CNS GvHD Study Grp. CNS manifestations in acute and chronic graft-versus-host disease. BRAIN. 2025; 148(4)DOI:10.1093/brain/awae340. PMID:39442000. IF:11.700(Q1/1D).

01/04/2025 The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide

Spyridonidis, A, Labopin, M, Savani, BP, Kulagin, A, Blaise, D, Broers, AEC, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, Itäla-Remes, M, von dem Borne, P, Esquirol, A, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2025; 60(4)DOI:10.1038/s41409-025-02514-4. PMID:39910175. IF:5.200(Q1/1D).

21/03/2025 Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

Jiménez-Vicente, C, Esteve, J, Baile-González, M, Pérez-López, E, Calvo, CM, Aparicio, C, Ormategi, IO, Esquirol, A, Peña-Muñoz, F, Fernandez-Luis, S, Fernando, IH, González-Rodríguez, AP, López-García, A, López-Lorenzo, JL, Torrado, T, Marín, AJS, Fleytas, CA, García, L, Villar, S, Filaferro, S, Balsalobre, P, Cascón, MJP, Salas, MQ. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01223-x. PMID:40118819. IF:11.600(Q1/1D).

05/03/2025 Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection

Navarro, S, Moukheiber, C, Sancho, SI, Guillén, MR, de Cerio, ALD, Sanges, C, Tanaka, T, Arnould, S, Briones, J, Dolstra, H, Hudecek, M, Choudhary, R, Schapitz, I, Juan, ME, Worel, N, Ammar, D, Luu, M, Mueller, M, Schroeder, B, Negre, H, Franz, P. Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection. MOLECULAR THERAPY. 2025; 33(3)DOI:10.1016/j.ymthe.2024.11.017. PMID:39533710. IF:12.000(Q1/1D).

01/03/2025 Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC

Escamilla-Gómez, V, Gutiérrez, VG, Alcalde-Mellado, P, Astibia-Mahillo, B, Chinea-Rodriguez, A, López-Corral, L, Acera-Gómez, M, Ochando, MKT, Borrego, AB, Pinedo, LG, Ripa, TZ, Vicent, MG, Benzaquén, A, García, II, Cantó, PA, Montoro, J, Martín-Domínguez, FM, Orti, G, Valcárcel, D, Benitez-Carabante, MI, Diaz-de-Heredia, C, Cañamero, E, Ferrá, C, García-Cadenas, I, Redondo, S, Sisinni, L, Perez-Martínez, A, Mussetti, A, Garcia-Mañó, L, Palomo-Moraleda, MD, González-Sierra, PA, Jurado, M, Perez-Simon, JA. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2025; 60(3)DOI:10.1038/s41409-024-02483-0. PMID:39663471. IF:5.200(Q1/1D).

01/02/2025 Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features

Sierro-Martinez, B, Escamilla-Gomez, V, Perez-Ortega, L, Guijarro-Albaladejo, B, Hernandez-Diaz, P, de la Rosa-garrido, M, Lara-Chica, M, Rodriguez-Gil, A, Reguera-Ortega, JL, Sanoja-Flores, L, Arribas-Arribas, B, Montiel-Aguilera, MA, Carmona, G, Robles, MJ, Caballero-Velazquez, T, Briones, J, Einsele, H, Hudecek, M, Perez-Simon, JA, Garcia-Guerrero, E. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. CELLULAR ONCOLOGY. 2025; 48(1)DOI:10.1007/s13402-024-00984-0. PMID:39192092. IF:4.800(Q1/1D).

11/01/2025 Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

Oñate, G, Garrido, A, Arnan, M, Pomares, H, Alonso, E, Tormo, M, Diaz-Beya, M, Vives, S, Zamora, L, Sampol, A, Coll, R, Salamero, O, Cervera, M, Garcia, A, Vall-Llovera, F, Garcia-Avila, S, Bargay, J, Ortin, X, Iranzo, E, Guijarro, F, Pratcorona, M, Nomdedeu, JF, Esteve, J, Sierra, J. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-024-01205-5. PMID:39799145. IF:11.600(Q1/1D).

07/01/2025 Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care

Salas, MQ, Solano, MT, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaría, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, González, SR, Mussetti, A, Lavilla, E, Lopez-Marín, J, Filaferro, S, Cedillo, A, Bento, L, Sureda, A. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care. Frontiers in Immunology. 2025; 15DOI:10.3389/fimmu.2024.1512154. PMID:39840039. IF:5.900(Q1/2D).

01/01/2025 Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

González-Gil, C, Morgades, M, Lopes, T, Fuster-Tormo, F, Montesinos, P, Barba, P, Díaz-Beya, M, Hermosín, L, Maluquer, C, González-Campos, J, Bernal, T, Arriaga, MS, Zamora, L, Pratcorona, M, Martino, R, Larrayoz, MJ, Artola, T, Torrent, A, Vall-llovera, F, Tormo, M, Gil, C, Novo, A, Martínez-Sánchez, P, Ribera, J, Queipo, MP, González-Martínez, T, Cabrero, M, Cladera, A, Cervera, J, Orfao, A, Ribera, JM, Genescà, E. Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. HAEMATOLOGICA. 2025; 110(1)DOI:10.3324/haematol.2024.285416. PMID:39113657. IF:10.100(Q1/2D).

01/01/2025 Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII

Bhambi-Blanco, I, González-Alvarez, N, San-José, P. Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII. ANNALES DE BIOLOGIE CLINIQUE. 2025; 83(-1)DOI:10.1684/abc.2025.1953. PMID:39953854. IF:0.400(Q4/10D).

01/01/2025 Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain

de Larrea, CF, Loscertales, J, Cabañas, V, Freiria, C, Blanchard, MJ, Askari, E, Perez, ML, Abril, L, Pardo, JL, Pinzón, S, Gálvez, JD, Amer, N, Páyer, AR, Sánchez, RG, Alcalá, MM, Capote, FJ, Moreno, D, Bolumburu, C, Rubio-Azpeitia, E, Sanz, RG. Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. Therapeutic Advances in Hematology. 2025; 16DOI:10.1177/20406207251379670. PMID:. IF:3.100(Q2/4D).

21/11/2024 Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Döhner, H, Dinardo, CD, Appelbaum, FR, Craddock, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Wei, AH, Löwenberg, B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. BLOOD. 2024; 144(21)DOI:10.1182/blood.2024025409. PMID:39133932. IF:23.100(Q1/1D).

12/11/2024 Cardiac events after allo-HCT in patients with acute myeloid leukemia

Salas, MQ, Cascos, E, López-García, A, Pérez, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Peña-Muñóz, F, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Dominguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, Garcia, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Cedillo, A, Orti, G, Chacón, MJ. Cardiac events after allo-HCT in patients with acute myeloid leukemia. Blood Advances. 2024; 8(21)DOI:10.1182/bloodadvances.2024013535. PMID:39178345. IF:7.100(Q1/2D).

29/10/2024 Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.

Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, Martin Lopez AA, Iraola-Truchuelo J, Delgado J, Perez A, Guerreiro M, Caballero AC, Martinez-Cibrian N, Luzardo Henriquez H, Sanchez Pina JM, Sancho JM, Ghesquieres H, Mussetti A, Lopez Corral L, Hernani R, Reguera JL, Sureda A, Bosch F, Martin Garcia-Sancho A, Kwon M, Subklewe M, Kuhnl A, Bachy E, Barba P, Villacampa G, Abrisqueta P. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.. Journal of Hematology & Oncology. 2024; 17(1)DOI:10.1186/s13045-024-01608-8. PMID:39468591. IF:(Q/D).

01/10/2024 Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO

Bailén, R, Iacoboni, G, Delgado, J, López-Corral, L, Hernani-Morales, R, Ortiz-Maldonado, V, Guerreiro, M, Caballero, AC, Guerra-Domínguez, ML, Sánchez-Pina, JM, Peña, M, Torrent, A, Pérez-Martínez, A, Bastos-Oreiro, M, Reguera-Ortega, JL, Martín, A, Hernandez-Boluda, JC, Martínez-Cibrián, N, Sanz, J, Briones, J, Henriquez, HL, Calbacho, M, Mussetti, A, Sancho, JM, Barba, P, Kwon, M. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.06.022. PMID:39069076. IF:4.400(Q1/1D).

01/10/2024 THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY

Spyridonidis, A, Labopin, M, Savani, B, Kulagin, A, Blaise, D, Versluis, J, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, It la-Remes, M, Borne, PV, Martino, R, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/10/2024 DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)

Serrano, JD, Corral, LL, Valc rcel, D, Sierra, J, Ferra-Coll, C, Velazquez, TC, Dom nguez, FM, Le n, RJ, Ortega, JLR, Go i, CB, L pez, EP, Mart nez, AC, Cadenas, IG, Sim n, JAP. DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/10/2024 DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT

Gagelmann, N, De Witte, M, Peczynski, C, Boreland, W, Broers, A, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Byrne, J, Bethge, W, Maertens, J, St lzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kr ger, N, Corradini, P, Finazzi, MC, Corral, L, Villar, S, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/10/2024 RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY

G mez, VE, Corral, LL, Mahillo, BA, Mellado, PA, Dom nguez, FMM, G mez, MA, Cant , PA, G mez, JM, Ochando, MT, Borrego, AB, Pinedo, LG, Ripa, MTZ, Vicent, MG, Vallejos, AB, Izquierdo, I, Cadenas, IG, Velao, SR, Musseti, A, Giro, EC, Moraleda, PP, Pascual, GO, Sierra, PAG, Garc a, L, Guti rrez, VG, P rez-Sim n, JA. RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/10/2024 FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC)

Salas, MQ, Solano, MT, Baile-Gonz lez, M, Acera-G mez, M, Fox, L, del Mar P rez-Artigas, M, Santamar a, A, Quintela-Gonz lez, MDC, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Gonz lez, SR, Mussetti, A, Lavilla, E, L pez-Marin, J, Cedillo, A, Bento, L, Sureda, A. FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/10/2024 OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY

Fern ndez-Barge, T, Dom nguez-Garcia, JJ, Escamilla, MS, Caballer, JS, Chorao, P, Boluda, JCH, Velao, SR, Cadenas, IG, Bufarull, RM, Estefania, RC, Alexandre, IF, Pe a, AG, Garc a, AT, Ruiz, RG, Luis, SF, San Miguel, EMO, Ara jo, MC, Pell n, SGD, Rodr guez, MAB. OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/10/2024 FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-CT)

Salas, MQ, Solano, MT, Baile-Gonzalez, M, Acera-G mez, M, Fox, L, Perez-Artigas, MD, Santamar a, A, Quintela-Gonz lez, MD, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Rodr guez-Gonz lez, S, Mussetti, A, Abuin-Blanco, A, Lopez-Mar n, J, Filarerro, S, Bento, L, Sureda, A. FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-CT). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

01/09/2024 Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study

Bobes, A, Tormo, M, Diaz-Beya, M, Beneit, P, Botella, C, Moreno, AF, Mayol, AS, Sangerman, MA, Bermejo, AY, Amigo, MD, Labrador, J, Guinon, AG, Garrido, A, Serrano, J, Polo, SV, Fortes, MG, Sayas, MJ, Bergua, JM, Olave, MT, Vall-Llovera, F, Bargay, J, Sanchez, MP, Boyero, RG, Diaz-Lopez, A, de la Fuente, A. Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study. Clinical Lymphoma Myeloma & Leukemia. 2024; 24DOI:. PMID:. IF:2.700(Q2/4D).

13/08/2024 PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT

Montoro, J, Ngoya, M, Kulagin, A, Giebel, S, Broers, AEC, Bramanti, S, Halahleh, K, Pérez-Simón, JA, Solano, C, Ozcelik, T, Blaise, D, Sanz, J, Henriques, M, de Latour, RP, Martino, R, Scheid, C, Fox, L, Gromek, T, Jurado, M, Sakellari, I, Van Gorkom, G, Matteucci, P, Nagler, A, Koc, Y, Glass, B. PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT. Blood Advances. 2024; 8(15)DOI:10.1182/bloodadvances.2024013328. PMID:38810260. IF:7.100(Q1/2D).

01/01/2022 Risk factors analysis according to regional distribution of white matter hyperintensities in a stroke cohort

Medrano-Martorell, S, Capellades, J, Jimenez-Conde, J, Gonzalez-Ortiz, S, Vilas-Gonzalez, M, Rodriguez-Campello, A, Ois, A, Cuadrado-Godia, E, Avellaneda, C, Fernandez, I, Merino-Pena, E, Roquer, J, Marti-Fabregas, J, Giralt-Steinhauer, E. Risk factors analysis according to regional distribution of white matter hyperintensities in a stroke cohort. EUROPEAN RADIOLOGY. 2022; 32(1)DOI:10.1007/s00330-021-08106-2. PMID:34117555. IF:5.900(Q1/2D).

01/01/2022 The Role of Vascular Imaging atReferral Centers in the Drip and Ship Paradigm

Flores, A, Sero, L, Gomez-Choco, M, Ustrell, X, Pellise, A, Vinas, J, Rodriguez, P, Monterde, A, Castilho, G, Rubiera, M, Amaro, S, Padros, MAF, Cardona, P, Marti-Fabregas, J, Molina, CA, Serena, J, Jimenez-Fabrega, FX, Purroy, F, Zaragoza-Brunet, J, Cocho, D, Palomeras, E, Kuprinski, J, Mas, N, Hernandez-Perez, M, Sanjurjo, E, Carrion, D, Costa, X, Barcelo, M, Monedero, J, Catena, E, Rybyeba, M, Diaz, G, de la Ossa, NP, Ribo, M. The Role of Vascular Imaging atReferral Centers in the Drip and Ship Paradigm. Journal of Stroke & Cerebrovascular Diseases. 2022; 31(1)DOI:10.1016/j.jstrokecerebrovasdis.2021.106209. PMID:34794029. IF:2.500(Q3/7D).

01/12/2021 Influence of study design on effects of mask wearing on fMRI BOLD contrast and systemic physiology - A comment on Law et al. (2021)

Scholkmann, F, Fischer, JB, Frisk, LK, Delgado-Mederos, R, Mayos, M, Highton, D, Wolf, U, Wolf, M, Durduran, T. Influence of study design on effects of mask wearing on fMRI BOLD contrast and systemic physiology - A comment on Law et al. (2021). NEUROIMAGE. 2021; 244DOI:10.1016/j.neuroimage.2021.118549. PMID:34508896. IF:7.400(Q1/2D).

01/12/2021 Progression of Large Vessel Disease in Patients With Giant Cell Arteritis-Associated Ischemic Stroke: The Role of Vascular Imaging A Case Series

Guisado-Alonso, D, Edo, MC, Alarcon, PVE, Garcia-Sanchez, SM, Font, MA, Romo, LM, Marrero-Gonzalez, P, Mengual, JJ, Castrillo, L, Montull, C, Corominas, H, Gomez-Choco, M. Progression of Large Vessel Disease in Patients With Giant Cell Arteritis-Associated Ischemic Stroke: The Role of Vascular Imaging A Case Series. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY. 2021; 27(8)DOI:10.1097/RHU.0000000000001498. PMID:32732523. IF:3.902(Q3/6D).

01/11/2021 Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

van Kammen, MS, de Sousa, DA, Poli, S, Cordonnier, C, Heldner, MR, van de Munckhof, A, Krzywicka, K, van Haaps, T, Ciccone, A, Middeldorp, S, Levi, MM, Hovinga, JAK, Silvis, S, Hiltunen, S, Mansour, M, Arauz, A, Barboza, MA, Field, TS, Tsivgoulis, G, Nagel, S, Lindgren, E, Tatlisumak, T, Jood, K, Putaala, J, Ferro, JM, Arnold, M, Coutinho, JM, Guisado-Alonso D., Cerebral Venous Sinus Thrombosis T. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology. 2021; 78(11)DOI:10.1001/jamaneurol.2021.3619. PMID:34581763. IF:29.907(Q1/1D).

12/10/2021 Cerebral and systemic physiological effects of wearing face masks in adults

Fischer, JB, Frisk, LK, Scholkmann, F, Delgado-Mederos, R, Mayos, M, Durduran, T. Cerebral and systemic physiological effects of wearing face masks in adults. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021; 118(41)DOI:10.1073/pnas.2109111118. PMID:34607955. IF:12.779(Q1/2D).

01/10/2021 Impact of general anesthesia on posterior circulation large vessel occlusions after endovascular thrombectomy

Terceno, M, Silva, Y, Bashir, S, Vera-Monge, VA, Cardona, P, Molina, C, Chamorro, A, de la Ossa, NP, Hernandez-Perez, M, Werner, M, Camps-Renom, P, Rodriguez-Campello, A, Canovas, D, Purroy, F, Serena, J. Impact of general anesthesia on posterior circulation large vessel occlusions after endovascular thrombectomy. International Journal of Stroke. 2021; 16(7)DOI:10.1177/1747493020976247. PMID:33573525. IF:6.948(Q1/2D).

01/09/2021 European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines

Steiner, T, Dichgans, M, Norrving, B, Aamodt, AH, Berge, E, Christensen, H, Fuentes, B, Khatri, P, Korompoki, E, Marti-Fabregas, J, Quinn, T, Toni, D, Zedde, M, Sacco, S, Turc, G. European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines. European Stroke Journal. 2021; 6(3)DOI:10.1177/23969873211024143. PMID:34746429. IF:5.894(Q1/2D).

01/09/2021 Bottlenecks in the Acute Stroke Care System during the COVID-19 Pandemic in Catalonia

Ramos-Pachon, A, Garcia-Tornel, A, Millan, M, Ribo, M, Amaro, S, Cardona, P, Marti-Fabregas, J, Roquer, J, Silva, Y, Ustrell, X, Purroy, F, Gomez-Choco, M, Zaragoza-Brunet, J, Canovas, D, Krupinski, J, Sala, NM, Palomeras, E, Cocho, D, Redondo, L, Repullo, C, Sanjurjo, E, Carrion, D, Lopez, M, Almendros, MC, Barcelo, M, Monedero, J, Catena, E, Rybyeba, M, Diaz, G, Jimenez-Fabrega, X, Sola, S, Hidalgo, V, Pueyo, MJ, de la Ossa, NP, Urra, X. Bottlenecks in the Acute Stroke Care System during the COVID-19 Pandemic in Catalonia. CEREBROVASCULAR DISEASES. 2021; 50(5)DOI:10.1159/000516309. PMID:34023822. IF:3.104(Q3/6D).

01/09/2021 Effectiveness of Thrombectomy in Stroke According to Baseline Prognostic Factors: Inverse Probability of Treatment Weighting Analysis of a Population-Based Registry

Rudilosso, S, Rios, J, Rodriguez, A, Gomis, M, Vera, V, Gomez-Choco, M, Renu, A, Matos, N, Llull, L, Purroy, F, Amaro, S, Terceno, M, Obach, V, Serena, J, Marti-Fabregas, J, Cardona, P, Molina, C, Rodriguez-Campello, A, Canovas, D, Krupinski, J, Ustrell, X, Torres, F, San Roman, L, Salvat-Plana, M, Jimenez-Fabrega, FX, Palomeras, E, Catena, E, Colom, C, Cocho, D, Baiges, J, Aragones, JM, Diaz, G, Costa, X, Almendros, MC, Rybyeba, M, Barcelo, M, Carrion, D, Lopez, MN, Sanjurjo, E, de la Ossa, NP, Urra, X, Chamorro, A. Effectiveness of Thrombectomy in Stroke According to Baseline Prognostic Factors: Inverse Probability of Treatment Weighting Analysis of a Population-Based Registry. Journal of Stroke. 2021; 23(3)DOI:10.5853/jos.2021.00962. PMID:34649384. IF:8.632(Q1/1D).

01/09/2021 Reasons for Not Performing Mechanical Thrombectomy A Population-Based Study of Stroke Codes

Guisado-Alonso, D, Martinez-Domeno, A, Prats-Sanchez, L, Delgado-Mederos, R, Camps-Renom, P, Abilleira, S, De la Ossa, NP, Ramos-Pachon, A, Cardona, P, Rodriguez-Campello, A, Molina, CA, Rudilosso, S, Marti-Fabregas, J. Reasons for Not Performing Mechanical Thrombectomy A Population-Based Study of Stroke Codes. STROKE. 2021; 52(9)DOI:10.1161/STROKEAHA.120.032648. PMID:34289711. IF:10.170(Q1/1D).

01/07/2021 Defining Minor Intracerebral Hemorrhage

Gomez-Gonzalez, A, Lazcano, U, Vivanco-Hidalgo, RM, Prats-Sanchez, L, Guisado-Alonso, D, Delgado-Mederos, R, Camps-Renom, P, Domeno, AM, Cuadrado-Godia, E, Steinhauer, EG, Jimenez-Conde, J, Soriano-Tarraga, C, Avellaneda-Gomez, C, Rodriguez-Campello, A, Marti-Fabregas, J, Ois, A, Roquer, J. Defining Minor Intracerebral Hemorrhage. CEREBROVASCULAR DISEASES. 2021; 50(4)DOI:10.1159/000515169. PMID:33831860. IF:3.104(Q3/6D).

01/02/2024 Serum from Stroke Patients with High-Grade Carotid Stenosis Promotes Cyclooxygenase-Dependent Endothelial Dysfunction in Non-ischemic Mice Carotid Arteries

Puertas-Umbert, L, Puig, N, Camacho, M, Dantas, AP, Marin, R, Marti-Fabregas, J, Jimenez-Xarrie, E, Benitez, S, Camps-Renom, P, Jimenez-Altayo, F. Serum from Stroke Patients with High-Grade Carotid Stenosis Promotes Cyclooxygenase-Dependent Endothelial Dysfunction in Non-ischemic Mice Carotid Arteries. Translational Stroke Research. 2024; 15(1)DOI:10.1007/s12975-022-01117-1. PMID:36536168. IF:4.300(Q1/2D).

11/04/2023 Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy

Bonaterra-Pastra A., Benítez S., Pancorbo O., Rodríguez-Luna D., Vert C., Rovira A., Freijo M.M., Tur S., Martínez-Zabaleta M., Portela, PC, Vera R., Lebrato-Hernández L., Arenillas J.F., Pérez-Sánchez S., Domínguez-Mayoral A., Fabregas, JM, Mauri G., Montaner J., Sánchez-Quesada J.L., Hernández-Guillamon M.. Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy. Frontiers in Aging Neuroscience. 2023; 15DOI:10.3389/fnagi.2023.1134399. PMID:37113571. IF:4.100(Q2/3D).

11/04/2023 Can Electronegative LDL Act as a Multienzymatic Complex?

Benitez, S, Puig, N, Rives, J, Sole, A, Sanchez-Quesada, JL. Can Electronegative LDL Act as a Multienzymatic Complex?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(8)DOI:10.3390/ijms24087074. PMID:37108253. IF:4.900(Q1/3D).

02/03/2023 Sex and gender differences in acute stroke care: metrics, access to treatment and outcome. A territorial analysis of the Stroke Code System of Catalonia

Silva, Y, Sanchez-Cirera, L, Terceno, M, Dorado, L, Valls, A, Martinez, M, Abilleira, S, Rubiera, M, Quesada, H, Llull, L, Rodriguez-Campello, A, Marti-Fabregas, J, Sero, L, Purroy, F, Payo, I, Garcia, S, Canovas, D, Krupinski, J, Mas, N, Palomeras, E, Cocho, D, Font, MA, Catena, E, Puiggros, E, Pedroza, C, Marin, G, Carrion, D, Costa, X, Almendros, MC, Torres, I, Colom, C, Velasquez, JA, Diaz, G, JimTnez, X, Subirats, T, Deulofeu, A, Hidalgo, V, Salvat-Plana, M, de la Ossa, NP. Sex and gender differences in acute stroke care: metrics, access to treatment and outcome. A territorial analysis of the Stroke Code System of Catalonia. European Stroke Journal. 2023; 8(2)DOI:10.1177/23969873231156260. PMID:37231687. IF:5.900(Q1/1D).

01/01/2023 Evolution of quality indicators in acute stroke during the RACECAT Trial: Impact in the general population

Olive-Gadea, M, de la Ossa, NP, Jovin, T, Abilleira, S, Jimenez, X, Cardona, P, Chamorro, A, Flores, A, Silva, Y, Purroy, F, Marti-Fabregas, J, Rodriguez-Campello, A, Zaragoza, J, Krupinski, J, Canovas, D, Choco, MG, Mas, N, Palomeras, E, Cocho, D, Aragones, JM, Repullo, C, Sanjurjo, E, Carrion, D, Catena, E, Costa, X, Almendros, MC, Barcelo, M, Monedero, J, Rybyeva, M, Diaz, G, Ribo, M. Evolution of quality indicators in acute stroke during the RACECAT Trial: Impact in the general population. International Journal of Stroke. 2023; 18(2)DOI:10.1177/17474930221093523. PMID:35373657. IF:6.300(Q1/1D).

01/01/2023 First pass effect in posterior circulation occlusions: Analysis from the CICAT registry

Terceno, M, Silva, Y, Bashir, S, Chamorro, A, de la Ossa, NP, Hernandez-Perez, M, Castano, C, Camps-Renom, P, Wenger, D, Cardona, P, Molina, C, Rodriguez-Campello, A, Canovas, D, Purroy, F, Salvat-Plana, M, Serena, J. First pass effect in posterior circulation occlusions: Analysis from the CICAT registry. International Journal of Stroke. 2023; 18(2)DOI:10.1177/17474930221089772. PMID:35272563. IF:6.300(Q1/1D).

01/01/2023 Presence of Ceramidase Activity in Electronegative LDL

Puig N., Rives J., Estruch M., Aguilera-Simon A., Rotllan N., Camacho M., Colomé N., Canals F., Sánchez-Quesada J.L., Benitez S.. Presence of Ceramidase Activity in Electronegative LDL. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1)DOI:10.3390/ijms24010165. PMID:36613609. IF:4.900(Q1/3D).

01/12/2022 Ischemia preconditioning induces an adaptive response that defines a circulating metabolomic signature in ischemic stroke patients

Sol, J, Colas-Campas, L, Mauri-Capdevila, G, Molina-Seguin, J, Galo-Licona, JD, Torres-Querol, C, Aymerich, N, Ois, A, Roquer, J, Tur, S, Garcia-Carreira, MD, Marti-Fabregas, J, Cruz-Culebras, A, Segura, T, Pamplona, R, Portero-Otin, M, Arque, G, Jove, M, Purroy, F. Ischemia preconditioning induces an adaptive response that defines a circulating metabolomic signature in ischemic stroke patients. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2022; 42(12)DOI:10.1177/0271678X221116288. PMID:35869638. IF:6.300(Q1/2D).

01/06/2022 Dual-Stentriever technique for retrieval of an unusual middle cerebral artery embolus

Martínez González, J.P., Guerrero Vara, R., Medina Iglesias, V., Branera Pujol, J., Camps Renom, P.. Dual-Stentriever technique for retrieval of an unusual middle cerebral artery embolus. NEUROLOGIA. 2022; 37(5)DOI:10.1016/j.nrl.2021.08.006. PMID:34509320. IF:3.900(Q1/3D).

10/05/2022 Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas The RACECAT Randomized Clinical Trial

de la Ossa, NP, Abilleira, S, Jovin, TG, Garcia-Tornel, A, Jimenez, X, Urra, X, Cardona, P, Cocho, D, Purroy, F, Serena, J, Manzanera, LS, Vivanco-Hidalgo, RM, Salvat-Plana, M, Chamorro, A, Gallofre, M, Molina, CA, Cobo, E, Davalos, A, Ribo, M, Martí-Fàbregas J., RACECAT Trial Investigators. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas The RACECAT Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2022; 327(18)DOI:10.1001/jama.2022.4404. PMID:35510397. IF:120.700(Q1/1D).

01/05/2022 Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source The Young ESUS Longitudinal Cohort Study

Perera, KS, Boasquevisque, DD, Rao-Melacini, P, Taylor, A, Cheng, A, Hankey, GJ, Lee, S, Fabregas, JM, Ameriso, SF, Field, TS, Arauz, A, Coutts, SB, Arnold, M, Mikulik, R, Toni, D, Mandzia, J, Veltkamp, RC, Meseguer, E, Haeusler, KG, Hart, RG, Young ESUS Investigators. Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source The Young ESUS Longitudinal Cohort Study. JAMA Neurology. 2022; 79(5)DOI:10.1001/jamaneurol.2022.0048. PMID:35285869. IF:29.000(Q1/1D).

31/03/2022 Isolated dilated pupil

Ruiz-Barrio, I, Guisado-Alonso, D, Bulnes-Gonzalez, V, Green, BT. Isolated dilated pupil. BMJ-British Medical Journal. 2022; 376DOI:10.1136/bmj-2021-069133. PMID:35361677. IF:105.700(Q1/1D).

01/03/2022 Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke The CHOICE Randomized Clinical Trial

Renu, A, Millan, M, San Roman, L, Blasco, J, Marti-Fabregas, J, Terceno, M, Amaro, S, Serena, J, Urra, X, Laredo, C, Barranco, R, Camps-Renom, P, Zarco, F, Oleaga, L, Cardona, P, Castano, C, Macho, J, Cuadrado-Godia, E, Vivas, E, Lopez-Rueda, A, Guimaraens, L, Ramos-Pachon, A, Roquer, J, Muchada, M, Tomasello, A, Davalos, A, Torres, F, Chamorro, A. Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke The CHOICE Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2022; 327(9)DOI:10.1001/jama.2022.1645. PMID:35143603. IF:120.700(Q1/1D).

01/03/2022 Predictors of Functional Outcome After Thrombectomy in Patients With Prestroke Disability in Clinical Practice

Millán M, Ramos-Pachón A, Dorado L, Bustamante A, Hernández-Pérez M, Rodríguez-Esparragoza L, Gomis M, Remollo S, Castaño C, Werner M, Wenger D, Rubio S, Domínguez-Lizarbe M, Terceño M, Paipa AJ, Rodríguez-Vázquez A, Boned S, Camps-Renom P, Cánovas D, Giralt E, López-Cancio E, Dávalos A, Ros-Roig J, Pérez de la Ossa N. Predictors of Functional Outcome After Thrombectomy in Patients With Prestroke Disability in Clinical Practice. STROKE. 2022; 53(3)DOI:10.1161/STROKEAHA.121.034960. PMID:34702065. IF:8.300(Q1/1D).

01/01/2022 Frequency and patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial

Sharma, M, Smith, EE, Pearce, LA, Shoamanesh, A, Perera, KS, Coutts, SB, Damgaard, D, Ameriso, SF, Rha, JH, Modrau, B, Yoon, BW, Romano, M, Messe, SR, Barlinn, J, Lambeck, J, Saad, F, Berkowitz, SD, Mundl, H, Connolly, SJ, Hart, RG, Marti-Fabregas, J, O'Donnell, MJ. Frequency and patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. STROKE. 2022; 53(1)DOI:10.1161/STROKEAHA.120.032976. PMID:34538089. IF:8.300(Q1/1D).

01/02/2026 Comment on: Development of a bladder injury classification system for endoscopic procedures: a mixed-methods study involving expert consensus and validation

Avesani, G, Gallioli, A, Di Bello, F, Breda, A, Palou, J. Comment on: Development of a bladder injury classification system for endoscopic procedures: a mixed-methods study involving expert consensus and validation. Minerva Urology And Nephrology. 2026; 78(1)DOI:10.23736/S2724-6051.25.06883-1. PMID:41697214. IF:4.200(Q1/2D).

01/02/2026 3D versus 2D laparoscopy for adrenal surgery: an international multicentric retrospective cohort study

Di Buono, G, Territo, A, Rodríguez-Hermosa, JI, Cornejo, L, Rodríguez-Mañé, M, Mantica, G, Terrone, C, Crisan, N, Andras, I, Esperto, F, Scarpa, RM, Breda, A, Casadevall, M, Citarrella, R, Amato, G, Romano, G, Lodico, M, Matranga, D, Agrusa, A. 3D versus 2D laparoscopy for adrenal surgery: an international multicentric retrospective cohort study. International Journal of Surgery. 2026; 112(2)DOI:10.1097/JS9.0000000000003964. PMID:41247879. IF:10.100(Q1/1D).